Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy

BACKGROUND: Tocilizumab, a humanized monoclonal antibody, targets IL-6 receptors blocking downstream pro-inflammatory effects of IL-6. In preliminary reports it was suggested to be beneficial in patients with severe COVID-19. METHODS: In this open-label prospective study we describe clinical charact...

Descripción completa

Detalles Bibliográficos
Autores principales: Morena, Valentina, Milazzo, Laura, Oreni, Letizia, Bestetti, Giovanna, Fossali, Tommaso, Bassoli, Cinzia, Torre, Alessandro, Cossu, Maria Vittoria, Minari, Caterina, Ballone, Elisabetta, Perotti, Andrea, Mileto, Davide, Niero, Fosca, Merli, Stefania, Foschi, Antonella, Vimercati, Stefania, Rizzardini, Giuliano, Sollima, Salvatore, Bradanini, Lucia, Galimberti, Laura, Colombo, Riccardo, Micheli, Valeria, Negri, Cristina, Ridolfo, Anna Lisa, Meroni, Luca, Galli, Massimo, Antinori, Spinello, Corbellino, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Federation of Internal Medicine. Published by Elsevier B.V. 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241995/
https://www.ncbi.nlm.nih.gov/pubmed/32448770
http://dx.doi.org/10.1016/j.ejim.2020.05.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241995/
https://www.ncbi.nlm.nih.gov/pubmed/32448770
http://dx.doi.org/10.1016/j.ejim.2020.05.011

Ejemplares similares